Radiotherapy is one of the first-line strategies for cancer treatment. However, radioresistance remains a major obstacle against effective radiotherapy. Recent advances in cancer research have underlined several intrinsic mechanisms that render cancer cells radioresistant. Additionally, cross-talk between tumor and myeloid cells in the tumor microenvironment (TME) comprises an important extrinsic mechanism that effects tumorigenicity and therapeutic resistance. Thus, factors affecting the biology of myeloid cells are expected to contribute to radioresistance and may serve as novel therapeutic targets to overcome radioresistance. Interleukin-34 (IL-34) is a hematopoietic cytokine that acts as a second ligand of CSF1R, in addition to the previously well-known ligand M-CSF. Both M-CSF and IL-34 regulate survival, proliferation and differentiation of myeloid lineage cells including monocytes, macrophages and osteoclasts. Importantly, IL-34 can be induced upon cellular stress and contributes to the pathogenicity of various diseases. In this study, we examined whether IL-34 expression could be induced in radiation-stressed cancer cells. In prostate and colon cancer cells, both M-CSF and IL-34 expressions were induced upon exposure to radiation. M-CSF expression showed a tendency to increase during the early phases (24-48 h), whereas IL-34 expression increased at later phases (72-96 h). Using various pharmacological inhibitors, we found that M-CSF and IL-34 expressions were regulated differentially by Abl and NF-kB, respectively. Repeated radiation exposure results in induced expression of both M-CSF and IL-34, with the expression of IL-34 stronger than that of M-CSF, consistent with its relation to chronic inflammatory conditions. Taken together, our results show that both M-CSF and IL-34 can be induced in radiation-stressed cancer cells, with a tendency for IL-34 to dominate upon repeated radiation exposure, which suggests important roles for IL-34 in radioresistance. Future work will focus on the impact of IL-34 on radiation-treated TME and the therapeutic potential of IL-34 targeting when accompanied by anti-cancer radiotherapy.
View full abstract